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Randomized, double-blind, placebo-controlled study of argi- A renewed interest toward l-arginine (ARG) grew
nine supplementation in chronic renal failure. when investigators identified it as the physiological pre-
Background. Supplementation with l-arginine (ARG) strik- cursor of nitric oxide (NO), the main endothelial-derivedingly ameliorates proteinuria and glomerulosclerosis in rem-
vasodilating factor [1, 2]. The plasma ARG level is main-nant rats by overcoming nitric oxide (NO) deficiency. Whether
tained constant mainly by dietary intake and renal syn-or not the same holds true in humans is unknown. This study
aimed at evaluating the effects of ARG on the NO system and thesis, with l-citrulline being the specific substrate [3].
renal function in proteinuric patients with moderate chronic ARG is converted into NO and citrulline by constitutive
renal failure (CRF).
and inducible NO synthase (NOS) isoforms, which areMethods. We measured plasma arginine, urinary and plasma
present in various cell types throughout the body andNO3 (an index of NO synthesis), and urinary cGMP (an intra-
cellular mediator of NO), as well as proteinuria and renal that lately have been identified in renal cells as well
functional reserve (RFR) in CRF patients orally treated for [2, 3]. In the kidney, NO plays a crucial role directly and
six months with either ARG (0.2 g/kg body wt/day, CRF-A through antagonism with angiotensin II (Ang II) [1, 4,group) or the control vehicle (CRF-C). Normal subjects (NOR)
5]. Experimental studies have demonstrated that NOwere also included for basal comparisons.
critically contributes to the maintenance of resting glo-Results. In CRF patients at baseline, plasma arginine was
within the normal range; similarly, the urinary excretion of merular vasodilation, as well as to the physiological renal
NO3 was comparable to the NOR value (CRF, 0.440 6 0.02; vasodilatory response to acute amino acid loading, the
NOR, 0.537 6 0.08 mmol/min, P 5 NS). The plasma NO3 levels so-called renal functional reserve (RFR) [4–6]. In vitrowere higher than in NOR (CRF, 74 6 6; NOR, 27 6 2 mmol/
studies have also shown that this substance acts as aliter, P , 0.001), and consequently the renal clearance of NO3
resulted as being reduced. During the six months of treatment, potent antiproliferative agent for renal cells [1, 3].
although a remarkable steadiness of ARG and NO3 levels was An adequate synthesis of NO is essential to the main-
detected in the CRF-C group, the CRF-A group was character- tenance of normal renal function and structure; there-
ized by a marked and immediate increase of plasma ARG.
fore, the possibility of enhancing its production in renalThis was associated, however, with a delayed increment in
diseases characterized by NO deficiency becomes ex-urinary and plasma NO3 levels and no change in urinary cGMP.
In CRF-A, as in CRF-C, blood pressure, proteinuria, glomeru- tremely intriguing. In the remnant rat model of chronic
lar filtration rate, and renal plasma flow did not vary. Likewise, renal failure (CRF), the renal synthesis of NO decreases
RFR, which was reduced at baseline in CRF, did not improve in parallel with the decline of renal function [7]. In thisafter ARG.
condition, chronic ARG supplementation leads to a re-Conclusions. In moderate CRF, the tonic release of NO is
duction of both proteinuria and glomerulosclerosis [8–constant and, likely, not impaired, and ARG supplementation
does not lead to an enhancement of NO activity, thus resulting 12]. The amelioration of renal outcome has been ascribed
in no renal effect. to the increased availability of ARG at the level of renal
NOS, with the consequent enhancement of NO genera-
tion that in turn reduces glomerular pressure and cellKey words: nitric oxide, nitrates, cGMP, proteinuria, renal functional
reserve. proliferation [8–12]. As a further support to the benefi-
cial action of NO in remnant rats is the recent observa-
Received for publication October 16, 1998
tion that the antiproteinuric effect of angiotensin-con-and in revised form March 18, 1999
Accepted for publication March 25, 1999 verting enzyme inhibition (ACEi) is actually mediated
by the increment of NO synthesis [11]. 1999 by the International Society of Nephrology
674
De Nicola et al: Arginine supplementation in renal failure 675
The involvement of the ARG/NO pathway in the con- mentation (CRF-A group, N 5 11) and control patients
receiving the vehicle of arginine as a placebo (CRF-Ctrol of systemic and renal vascular tone has been con-
firmed in humans. Acute or short-term ARG administra- group, N 5 10). We excluded from the study patients
with diabetes mellitus, neoplastic disease, heart or livertion induces systemic hypotension and renal vasodilation
in healthy subjects and in hypertensive and cirrhotic pa- failure, proteinuria of more than 3 g/day, uncontrolled
hypertension with blood pressure constantly higher thantients and improves endothelium-dependent vasodila-
tion in hypercholesterolemic and hypertensive patients, 140/90 mm Hg, salt-losing nephritis, and patients with
creatinine clearance varying by more than 30% in theas well as in aging and in patients with heart failure
[13–18]. last six months before study. During the study, patients
were not allowed to take on a regular basis any medica-Despite these encouraging clinical findings and the
impressive body of evidence on the nephroprotective tion other than clonidine and doxazosin to control hyper-
tension and oral sodium bicarbonate to normalize bloodeffects in remnant rats, to date no study has concurrently
explored the metabolic fate and the renal effects of exog- pH. An adequate intake of calories (40 to 45 kcal/kg/
day) were prescribed throughout the study period and,enous ARG in patients with renal failure. Also, the mod-
ulation of endogenous ARG/NO pathway in renal failure according to the individual level of renal function and
proteinuria, a controlled intake of protein (0.6 to 1.0 g/remains controversial [19, 20].
The aim of this study was to evaluate in proteinuric kg/day) and sodium (5 to 8 g NaCl/day). No patient
developed protein-calorie malnutrition during the study.patients with moderate CRF (a) the ARG/NO pathway
in basal state and (b) the effects of oral supplementation Healthy volunteers were included in the study for the
assessment of RFR, plasma arginine, citrulline and orni-for six months with ARG on this system and renal func-
tion. We have analyzed the urinary and plasma concen- thine levels, and plasma and urinary nitrate levels (NOR
group, N 5 8). Normal status was defined by history,tration of nitrate (NO3), the stable end-product of NO
[21, 22], and the urinary levels of cGMP, that is, the physical examination, and laboratory analyses. During
the week prior to the assessment of renal clearancesintracellular mediator of NO [2, 3], which are both mark-
and nitrates, NOR subjects switched to a controlled salters of the production/activity of NO. To identify the
intake in order to match the level of dietary sodium ofpotential nephroprotective effects of ARG, we have
patients.monitored the level of proteinuria. Indeed, our period
Cigarette smoking was considered a criterion for ex-of follow-up is not long enough to observe substantial
clusion from the study because it influences the excretionchanges in the rate of glomerular filtration rate (GFR)
rate of nitrate [27]. All subjects had a complete ultra-decline, but it is certainly adequate to detect an eventual
sound evaluation of the urinary tract to exclude the pres-antiproteinuric response, which is a main predictor of
ence of obstruction.benign renal prognosis [23, 24]. We have also assessed
RFR before and after ARG treatment because the mag-
Study protocolnitude of GFR response to amino acid loading is possibly
In the last six months preceding the basal study, pa-determined by the status of the NO/Ang II balance, and
tients were seen every two months to verify the adher-moreover, it is correlated with the renal outcome [4, 5,
ence to the prescribed diet and to measure blood pres-25, 26].
sure and 24-hour creatinine clearance and proteinuria.
Only patients fulfilling the inclusion criteria were al-
METHODS lowed to the basal study.
The study was performed in 24 proteinuric patients The renal clearance studies were performed only if
aged 18 to 60 years with a moderate to medium degree the daily urinary excretion of sodium and creatinine did
of CRF (basal creatinine clearance, 20 to 70 ml/min) not differ more than 10 and 20%, respectively, in the
resulting from biopsy-proven primary glomerulonephri- last three days before sampling.
tis (GN). They were periodically seen in the out-patient At 9:00 a.m. of the day of the basal study, in all subjects,
clinic for the conservative treatment of renal failure for after overnight fasting, blood pressure, body weight, and
at least eight months prior to the study. All subjects gave heart rate were recorded, and plasma and 24-hour uri-
written informed consent before starting the protocol, nary samples were collected. Seated blood pressure was
which was approved by the local ethical committee. The measured after 10 minutes of rest with a mercury sphyg-
study drug was discontinued in three patients because momanometer. The mean of three consecutive measure-
of gastric intolerance (placebo), acute hepatitis B virus ments was reported. The levels of total protein, creati-
(HBV) infection (placebo), and acute bleeding from gas- nine, urea nitrogen, sodium and potassium, phosphate,
tric ulcer (arginine). and osmolality were measured in both plasma and urine.
After basal evaluation, patients were randomized in In CRF patients, plasma renin activity (PRA) and plasma
levels of insulin, arginine, citrulline, and ornithine weretwo groups: patients orally treated with arginine supple-
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measured. Serum bicarbonate and pH were determined to measure hematocrit, protein, albumin, electrolytes,
osmolality, and the blank value for para-amino hyppur-in samples of arterial blood. In both groups of patients,
the urinary levels of cGMP, the intracellular mediator ate sodium (PAH) and inulin levels (T0). Subsequently,
a priming bolus of PAH (0.05 ml/kg of 20% PAH) andof NO were also assessed.
We determined the plasma and urinary levels of ni- inulin (0.5 ml/kg of a 10% inulin) diluted in 50 ml of 5%
glucose solution was injected and immediately followedtrates in all study subjects to gain information on NO
synthesis. In the CRF groups, the measurements were by a constant infusion (1 ml/min) of inulin (125 mg/
creatinine clearance) and PAH (12.5 mg/estimated RPF)also obtained at the two-, four- and six-month visits.
Dietary intake of nitrates was reduced in the three days diluted in 500 ml of 5% glucose solution. This rate of
infusion permits constant maintenance the plasma con-preceding each control to ensure the best assessment of
NO production. Study subjects were instructed to eat centrations of the two markers [28, 29]. A 45-minute
equilibration period was allowed prior to starting mea-only fresh food (that is, without preservative substances)
and to avoid food with high nitrate content, such as fruit, surements; at the end of this period, subjects were asked
to void the bladder, and samples for basal inulin andleafy green vegetables, and cured meat. They were also
asked not to drink tap water because it contains variable PAH concentrations were drawn. Three renal clearances
were obtained, with the subjects voiding their bladderamounts of nitrate. This low-nitrate diet essentially in-
cluded pastas and low-nitrate vegetables (beans, peas, every 30-minute period. Urine and blood samples were
collected at each interval for the determination of PAH,carrots, cauliflower, onion, and leek).
Following this basal evaluation, in the same day, renal inulin, electrolytes and osmolality, serum protein, albu-
min, and hematocrit.clearance studies were performed to evaluate renal func-
tion and RFR. Thereafter, CRF patients were randomly To assess RFR, a constant infusion of a commercially
available standard amino acid mixture (Solamin Forte,assigned, in a double-blind fashion, to the six-month oral
treatment with either ARG-hydrochloride in saccarose 7.5%; Pierrel Ospedali, Milan, Italy) was given at a rate
of 240 ml/hr. This amino acid solution contains leucinesolution at 10% (Bioarginina, Damor, Naples, Italy) at
the dosage of 0.2 g/kg body wt/day (CRF-A group) or 6.6 g/liter, arginine 10.5 g/liter, isoleucine 4.2 g/liter, va-
line 4.8 g/liter, lysine 4.8 g/liter, glycine 12.75 g/liter,its vehicle (CRF-C group). Preliminary studies have de-
scribed that a two-month oral administration of this dose proline 1.5 g/liter, alanine 1.5 g/liter, threonine 3 g/liter,
histidine 6.75 g/liter, serine 1.5 g/liter, methionine 6.6 g/is associated with a reduction of proteinuria in children
with CRF (abstract; Claris-Appiani et al, J Am Soc liter, aspartic acid 1.2 g/liter, phenylalanine 6.6 g/liter,
tryptophan 1.5 g/liter, glutamic acid 0.75 g/liter, and tyro-Nephrol 4:766A, 1993). The assigned amount of study
drug was fractionated in three doses given at the time sine 0.45 g/liter. After 60 minutes of equilibration, sub-
jects were asked to void the bladder. Three 60-minuteof breakfast, lunch, and dinner.
After basal evaluation, the CRF patients of both renal clearance periods were performed, and the subjects
voided their bladder every hour. Urine and blood sam-groups continued the study and were seen in the outpa-
tient clinic every two weeks to obtain measurements of ples were collected at each interval for determinations
as in the basal study. Urine losses were replaced through-blood pressure, arterial pH, and bicarbonate. Patients
returned at month 2, 4, and 6 to repeat the evaluation out the study via a cannula placed in the contralateral
antecubital vein. Blood pressure and heart rate wereof renal function, proteinuria, and ARG/NO system by
the same determinations of the basal study. At the end measured at 30-minute intervals.
of follow-up, the plasma levels of citrulline and ornithine
Laboratory methodswere again measured, and the renal clearances were re-
peated to assess the effect of treatment on both resting Blood and urinary concentrations of protein, creati-
nine, nitrogen, phosphate, inulin, and PAH were ana-and stimulated renal function.
lyzed using standard techniques described in previous
Renal clearance studies articles [28, 29]. Blood samples for measurements of
PRA concentration were collected at room temperature;The assessment of resting renal function and RFR
was obtained in the two groups of patients and in NOR plasma was then separated and frozen until the time of
the assay, which did not exceed four weeks. PRA wassubjects. Patients repeated the study at the end of the six-
month treatment with either arginine or placebo. Studies measured by a radioimmunoassay (RIA) technique using
commercial kits (DPC, Los Angeles, CA, USA). Thestarted at 10:00 a.m. following overnight fasting. The
temperature (228C) and the lights of the study room urinary concentrations of cGMP were assessed by RIA
kit (cGMP [125I] assay system; Amersham, Little Chal-were maintained at constant levels. The subjects drank
10 ml/kg body wt of tap water over a 60-minute period font, Buckinghamshire, UK) [29]. Plasma insulin level
was measured using a 125I-insulin RIA kit (DPC). Theto facilitate diuresis. At 11:00 a.m., blood was taken, via
a cannula previously introduced into an antecubital vein, levels of K1 and Na1 were measured by ion-select-
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ive electrodes (Beckman E2Ana/K system, Arlington acid analyzer (Mod. 3A 30; Fisons Instruments, Milan,
Italy) employing lithium buffers, as previously describedHeights, IL, USA). Osmolality was determined by using
a standard microsmometer. [31].
The urinary excretion of NO3 was measured in timed
Calculationstwo- to four-hour urine collections from the second void-
ing of the morning. Fresh urine samples were preferred Glomerular filtration rate and renal plasma flow
(RPF) were estimated from the renal clearances of inulinto 24-hour urine in order to minimize the risk of bacterial
contamination; indeed, preliminary studies in four nor- and PAH, respectively, and were corrected by body sur-
face area (ml/min/1.73 m2). Effective RPF was calculatedmals and five CRF patients have demonstrated compara-
ble values of UNO3V in the two different periods of urine by dividing the corresponding PAH clearance by an esti-
mate of the renal extraction ratio [28, 29]. Renal bloodcollection. To the same purpose, the determination of
urinary nitrate was always performed in sterile urine, as flow (RBF), filtration fraction (FF), and renal vascular
resistance (RVR) were calculated as previously reporteddemonstrated by negative urine analysis and culture.
Furthermore, immediately after voiding in a sterile cylin- [28, 29]. RFR was calculated as the difference between
stimulated GFR (aaGFR) and baseline GFR (bas-der, 5 ml of sample were aspirated with a sterile syringe,
filtered through a minifilter (0.22 m) of cellulose acetate alGFR): (aaGFR-basalGFR) · 100/basalGFR, where
basalGFR is the mean value of the three clearance peri-(Millipore, Mollsheim, France) into a sterile Vacutainer
(Becton Dickinson Vacutainer Systems, Rutherford, NJ, ods of the resting phase and aaGFR is the mean value
of the three clearance periods of the amino acid infusionUSA), and stored at 2208C. A similar procedure was
used to process plasma samples. The absence of bacterial phase.
Protein intake was calculated from the following equa-contamination was confirmed by the minimal presence
of nitrite (,3 mmol/liter) detected by the standard Griess tion [28]: estimated protein intake (g/day) 5 6.25 · [UUN
(g/day) 1 SBW (kg) · 0.03 (g/kg SBW/day)], where SBWassay in random plasma and urine samples. Because of
the virtual absence of nitrite, we considered for the final is the standard body weight. Urea nitrogen appearance
was also calculated according to standard formula [32].statistical analysis only the levels of nitrates. Gilliam
et al have previously described a spectrophotometric The renal clearance of NO3 was calculated as U ·
V/P, where U is the urinary concentration, V is the uri-enzymatic method for measurement of nitrate levels in
biologic fluids using reduced nicotinamide adenine dinu- nary volume, and P is the mean plasma concentration
between the start and the end point of the clearancecleotide phosphate (NADPH) oxidation by the Aspergil-
lus nitrate reductase [30]. We have recently applied this period. The fractional tubular reabsorption (TR) of NO3
was calculated as 100, which is the value of percentageenzymatic method to a random access autoanalyzer [27].
The following reagents were used (Sigma Chemical Co., fractional excretion.
St. Louis, MO, USA): dipotassium hydrogen phosphate
Statistical analysis(K2HPO4, catalog P3786), potassium dihydrogen phos-
phate (KH2PO4, catalog P0662), flavin adenine dinucleo- Data are presented as mean 6 sem. We used one-
way analysis of variance for intergroup comparisons, andtide (FAD; catalog F6625), NADPH reduced (catalog
201201), nitrate reductase (catalog N7265), and sodium analysis of variance for repeated measures to detect
changes within the same group. Bonferroni’s correctionnitrate (catalog S5506). The autoanalyzer used was Co-
bas Mira plus (Roche, Milano, Italy). Briefly, according was used as the post hoc analysis. A P value of less than
0.05 was considered statistically significant.to our previous work [27], 7 ml of serum and urinary
sample were added to 100 ml of a work solution con-
taining potassium phosphate buffer at pH 7.5 (140 mm),
RESULTS
FAD (0.1 mm), and NADPH (1 mg) and to 12 ml of
Basal characteristics of study groupsAspergillus nitrate reductase (1.15 U/ml), to a final dilu-
tion of 1/21. The reaction was monitored at 340 nm for The clinical characteristics of healthy volunteers and
patients after randomization are reported in Table 1.10 minutes, measuring the decrease of absorbance as
index of oxidation of NADPH. Because of the possible The two groups of patients, CRF-A and CRF-C, were
homogeneous with regards to age, gender, creatinineinterference of normal serum analytes on NO3 determi-
nation, serum nitrate levels were measured by a standard clearance, proteinuria, and mean arterial pressure
(MAP). Also, the nutritional status was analogous, asaddition method where known amounts (50 and 100
mmol/liter) of nitrates were added to the serum speci- demonstrated by similar body weight, protein and phos-
phate intake, serum total protein (6.8 6 0.1 and 6.8 6men, and the NO3 concentration was estimated by the
difference between recorded and added nitrates. 0.2 g/dl), and serum albumin (4.1 6 0.1 and 4.2 6 0.1 g/
dl). At baseline, daily urinary volume (2108 6 135 andThe analysis of plasma levels of arginine, citrulline,
and ornithine was performed in triplicate by an amino 1825 6 113 ml), serum sodium (141 6 1.0 and 141 6 0.9
De Nicola et al: Arginine supplementation in renal failure678
Table 1. Clinical characteristics of normal subjects (NOR), and patients with moderate chronic renal failure prior to treatment with either
l-arginine (CRF-A) or placebo (CRF-C)
CRF-A CRF-C NOR
(11) (10) (8)
Age years 4563 5164 40 64
Sex M/F 8/3 7/3 6/2
Body weight kg 68.663.9 63.063.7 69.0 64.0
Renal disease 5 IgA, 2 Msp, 2 MP, 2 FS 2 IgA, 1 MsP, 2 MP, 2 FS, 2 M —
MAP mm Hg 9562 10164 90 64.0
Antihypertensive drugs N 1.060.3 1.160.2 —
Serum creatinine mg/dl 2.360.3 2.460.3 1.060.2a
Creatinine clearance ml/min 44.265.7 34.965.3 10965.0a
Hb g/dl 13.860.6 13.360.5 15.360.6a
Serum bicarbonate mEq/liter 23.460.6 22.960.3 27.060.8a
Protein intake g/kg/day 0.9260.06 0.7760.06 1.4 60.08a
Phosphate intake mg/kg/day 1361 1261 1962a
Urinary protein g/day 1.860.3 1.960.4 —
UNaV mEq/day 162613 123615 158 615
FENa (%) 2.160.1 2.060.3 0.860.2a
Data are mean 6 sem. Abbreviations are: IgA, Berger’s disease; MsP, diffuse mesangial proliferative glomerulonephritis; MP, membranoproliferative glomerulone-
phritis; FS, focal sclerosis; M, membranous glomerulonephritis; MAP, mean arterial pressure; Hb, hemoglobin; UNaV, urinary sodium excretion; FENa, fractional
urinary sodium excretion.
a P , 0.05 vs. other groups
Table 2. Plasma and urinary levels, renal clearance and tubular nary studies (data not shown), we have observed that
reabsorption of nitrates (NO3) in normal subjects (NOR), and the excretion of nitrate measured in the urine collectedin all patients with moderate chronic renal failure prior to
active treatment (CRF) in the morning is largely representative of the 24-hour
excretion rate. Such an observation is consistent withCRF (21) NOR (8) P
data of previous studies [21, 22].
UNO3 Vlmol/min 0.44060.022 0.537 60.077 NS As depicted in Figure 1, the basal plasma argininePlasma NO3
lmol/liter 74.066.0 26.6 62.5 ,0.001 level was within the normal range in both groups of CRF
ClNO3 ml/min 7.061.1 21.663.8 ,0.001 patients. Indeed, the mean values in CRF-A and CRF-C
NO3 reabsorption % 80.261.7 79.4 63.5 NS (88 6 8 and 94 6 6 mmol/liter, respectively) did not
Data are mean 6 sem. differ from the level measured in the group of healthy
volunteers (95 6 7 mmol/liter). Arginine supplementa-
tion determined a marked increase of plasma arginine
levels above the normal range since the second-monthmEq/liter), and serum osmolality (308 6 2 and 305 6 2
visit, whereas no change was detected in the placebomOsm/liter) were not different in ARG and CON. These
group. These data demonstrate the compliance to thedata and the comparable values of absolute and frac-
prescription. Plasma nitrate increased in the CRF-Ational urinary excretion of sodium demonstrated a simi-
group, with the final value doubling the basal level, whichlar volume and hydration state in the two groups of
was associated with a similar increment in the urinarypatients. Accordingly, PRA was not different in ARG
excretion of NO3. Notably, the enhancement of NO3 inand CON (1.7 6 0.4 and 3.0 6 0.6 ng/ml/hr, respectively).
plasma and urine mainly occurred in the last two months
Arginine/nitric oxide pathway prior to and during of observation; it was therefore delayed in comparison
arginine treatment with the early increment of plasma arginine. In patients
receiving placebo, both plasma and urinary NO3 resultedTable 2 shows the renal handling of nitrates in un-
as being fairly stable. The renal clearance of nitrates didtreated CRF and NOR subjects. In patients, the urinary
not change during follow-up in both groups of patients.excretion of NO3 was found to be only slightly reduced
Similarly, the TR of NO3 did not vary, remaining approx-in the presence of a plasma value almost threefold higher
imately 80% of the filtered load during the entire periodthan in healthy volunteers. Consequently, the renal clear-
of observation.ance of nitrates was threefold lower in CRF with respect
In the CRF-A group, at variance with the nitrate lev-to NOR subjects, as the GFR value. The TR of nitrates
els, the urinary excretion of cGMP did not changewas similar in the CRF and NOR group, being 80% of
throughout the study (Table 3).the filtered load in both groups. Of note, in the NOR
Table 4 depicts the plasma levels of ornithine andgroup, the plasma and urinary levels of nitrate, as well
citrulline in basal state and after the six-month courseas the renal handling of NO3, are comparable with the
reports of other investigators [21, 22, 33, 34]. In prelimi- of treatment. At baseline, the plasma ornithine in CRF
De Nicola et al: Arginine supplementation in renal failure 679
Table 3. Urinary cGMP excretion rate (pm/min) during follow-up
in patients with moderate chronic renal failure treated with either
l-arginine (CRF-A) or placebo (CRF-C)
Months
Basal 2 4 6
CRF-A 289624 247627 276633 303623
CRF-C 275621 291631 256630 280624
Data are mean 6 sem.
Table 4. Plasma levels (mm/liter) of ornithine and citrulline, in
normal subjects (NOR), and in patients with moderate chronic
renal failure at baseline and after 6 months of treatment with
either l-arginine (CRF-A) or placebo (CRF-C)
Basal Final
CRF-A
Ornithine 67.264.5 93.568.3a
Citrulline 53.462.7 53.663.5b
CRF-C
Ornithine 67.862.0 76.866.5
Citrulline 60.963.1 68.364.8a
NOR
Ornithine 6563 —
Citrulline 37 63c —
Data are mean 6 sem.
a P , 0.05 vs. basal
b P , 0.05 vs. CRF-C
c P , 0.05 vs. other groups
groups was similar to the normal value, whereas plasma
citrulline values were higher. During follow-up, almost
a 40% increase of ornithine levels was detected in
CRF-A, whereas no difference was observed in placebo-
treated patients.
Clinical data during the six-month period of follow-up
in chronic renal failure patients
Table 5 shows the outcome of renal function. In both
groups of patients, blood pressure remained constantly
normal in the absence of changes of antihypertensive
therapy. Similarly, patients did not experience changes
in creatinine clearance and urinary protein excretion,
these data being therefore compatible with a stable de-
gree of renal function and damage.
Body weight slightly increased in arginine-treated pa-
tients with respect to the placebo group. The difference
was marginally significant, with the final variation of
body weight averaging 12.3 6 0.9% in CRF-A, whereas
it was 20.1 6 1.0% in CRF-C (P 5 0.071). The absence
Fig. 1. Plasma levels of arginine (A), plasma nitrates (B), and urinary of a significant anabolic effect of arginine was associated
excretion of nitrates (C) in patients with moderate renal failure treated with a constant release of insulin. In fact, plasma insulinwith arginine (solid line) or placebo (dotted line) at baseline and during
that was similar at baseline (9.4 6 2.0 in CRF-A andfollow-up. The gray area indicates the normal range attained from
measurements in the normal group. *P , 0.05 vs. basal; dP , 0.05 vs. 12.1 6 1.7 mU/ml in CRF-C) did not vary during the
placebo group.
study. An expansion of extracellular volume in CRF-A
patients can be excluded because the daily sodium excre-
tion resulted unmodified throughout the follow-up in
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Table 5. Clinical data during follow-up in patients with moderate chronic renal failure treated with either
l-arginine (CRF-A) or placebo (CRF-C)
Months
Basal 2 4 6
CRF-A
MAP mm Hg 9562 94 62 94 63 97 62
Body weight kg 68.663.9 69.4 63.7 69.3 63.7 70.1 63.8
Serum albumin g/dl 4.160.1 4.4 60.1 4.2 60.1 4.0 60.1
CCr mlmin 44.265.7 46.1 65.3 44.2 65.3 44.5 64.8
Urinary output ml/day 21086167 2174 6114 2300 6176 2453 6185a
Uprot g/day 1.860.3 2.8 60.4 2.9 60.5 2.6 60.5
BUN mg/dl 32.662.5 41.2 63.2a 40.162.3a 42.262.5a
UUN g/day 7.860.8 10.860.8a 10.360.7a 10.660.7a
Urinary phosphate mg/day 536644 570 667 548 660 649 659
UNaV mEq/day 167617 164 65 158 610 165 68
Serum osmolality mOsm/liter 30863 317 64a 31663a 31562a
UOsmV mOsm/day 667649 776 650a 794647a 834634a
CRF-C
MAP mm Hg 10164 99 63 10163 96 63
Body weight kg 63.063.7 63.7 63.9 62.9 63.7 62.8 63.8
Serum albumin g/dl 4.260.1 4.4 60.1 4.4 60.1 4.2 60.1
CCr ml/min 34.964.3 33.8 63.9 35.3 64.6 33.5 64.0
Urinary output ml/day 18256144 1615 6171 1594 6119 1757 6150
Uprot g/day 1.960.4 2.8 60.5 2.6 60.5 2.1 60.3
BUN mg/dl 29.262.8 32.9 63.8 31.1 63.6 30.3 63.5
UUN g/day 5.760.7 6.0 60.8 5.8 60.9 5.5 60.9
Urinary phosphate mg/day 447642 411 624 418 630 370 641
UNaV mEq/day 123620 129 622 113 617 114 620
Serum osmolality mOsm/liter 30563 312 64 310 64 307 64
UOsmV mOsm/day 548668 548 674 502 662 512 675
Data are mean 6 sem. Abbreviations are: MAP, mean arterial pressure; CCr, creatinine clearance, Uprot, urinary protein excretion; BUN, blood urea nitrogen; UUN,
urea nitrogen excretion; UNaV, urinary sodium excretion; UOsmV, urinary excretion of osmoles.
a P , 0.05 vs. basal
both groups of CRF patients, thereby testifying to the with the enhancement of both serum osmolality and uri-
maintenance of a constant salt intake. Similarly, the frac- nary excretion of osmoles. We also measured the urea
tional urinary sodium excretion remained stable in both nitrogen appearance (UNA) to obtain a more proper
groups, the final value being 2.2 6 0.4% in CRF-A and assessment of nitrogen balance [32]. In patients receiving
1.9 6 0.3% in CRF-C. These data and the constancy of arginine supplementation, the variation of UNA, with
blood pressure, serum total protein, and hematocrit lev- respect to the basal value, was constantly positive [D
els testify of a steady volume status in both groups of UNA (g/day): 2.2 6 1.1, 1.5 6 1.0 and 3.9 6 1.3 at the
patients. second, fourth, and sixth month, respectively), whereas
During follow-up, the group of patients receiving negligible differences were observed in the placebo
ARG hydrochloride was characterized by a tendency to group (D UNA: 1.3 6 1.3, 21.0 6 1.2, and 20.4 6 1.3).
metabolic acidosis. CRF-A patients required a greater
amount of sodium bicarbonate (1 to 3 g/day), associated Unstimulated and stimulated glomerular filtration
with a proportionally lower salt intake in order to keep rate prior to arginine treatment and at the
constant the sodium intake. Thus, the arterial pH that end of follow-up
was at baseline 7.35 6 0.01 in CRF-A and 7.34 6 0.01
Table 6 shows basal renal hemodynamics in CRFin CRF-C did not vary throughout the study.
groups and healthy volunteers, as well as the hemody-Despite the stability of volume, a significant increase
namic response to treatment in both groups of patients.of PRA was detected in arginine-treated patients after
In CRF-A and CRF-C, the constancy of renal functionthe second month of treatment (3.1 ng/ml/hr, P , 0.05
during the six-month period of observation was con-vs. the basal value of 1.7 6 0.4), and it did not change
firmed by the renal clearances of inulin and PAH. In fact,subsequently (final, 2.9 6 0.3 ng/ml/hr, P , 0.05 vs.
basal GFR and renal hemodynamics were comparable inbasal). No change was observed in the placebo group
the two CRF groups and did not change at the end of(from 3.0 6 0.7 to 3.4 6 0.5 ng/ml/hr).
follow-up. Also, the Htc value was analogous at baselineIn contrast with the late rise of NO3 levels, the blood
in untreated and arginine-treated patients (45.9 6 1.7%and urinary levels of urea nitrogen promptly increased in
response to arginine supplementation. This was coupled and 43.0 6 2.2%, respectively), and resulted unmodified
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Table 6. Renal hemodynamics in normal subjects (NOR), and in
patients with moderate chronic renal failure at baseline and after
6 months of treatment with either l-arginine (CRF-A) or
placebo (CRF-C)
Basal Final
CRF-A
GFR ml/min/1.73 m2 33.064.1 34.8 65.1
ERPF ml/min/1.73 m2 291646 307 655
FF % 12.361.8 13.3 62.5
MAP mm Hg 9562 97 62
RVR mm Hg/ml/min/1.73 m2 0.21960.034 0.258 60.044
CRF-C
GFR ml/min/1.73 m2 29.563.7 29.4 63.9
ERPF ml/min/1.73 m2 235627 254 630
FF % 12.961.4 11.7 61.1
MAP mm Hg 10164 96 63
RVR mm Hg/ml/min/1.73 m2 0.28960.040 0.276 60.049
NOR
GFR ml/min/1.73 m2 10363a —
ERPF ml/min/1.73 m2 428612a —
FF % 24.561.2a — Fig. 2. Amino acid-induced change from baseline of glomerular filtra-
MAP mm Hg 9064 — tion rate (GFR; ) and renal plasma flow ( ) in normal subjects and
RVR mm Hg/ml/min/1.73 m2 0.11560.041a — in chronic renal failure patients treated with arginine (ARG) or placebo
(Con) at baseline and after the six-month period of treatment. *P ,Data are mean 6 sem. Abbreviations are: GFR, glomerular filtration rate:
0.05 vs. other groups.ERPF, effective renal plasma flow; FF, filtration fraction; MAP, mean arterial
pressure; RVR, renal vascular resistance.
a P , 0.05 vs. other groups
entirely dependent on the decreased renal uptake [31].
Our data suggest that in CRF, the adequate conversionafter treatment (42.5 6 1.3% and 42.9 6 2.6%, respec-
of arginine into NO, which is coupled with the releasetively).
of citrulline [1, 3] contributes to the observed incre-As depicted in Figure 2, the renal response to the
ment of this amino acid. This study provides first-timeacute amino acid load was reduced in CRF patients and
evidence that the endogenous NO production is constantdid not vary following the assigned treatment. Indeed,
in moderate CRF. During the six months of follow-up,RFR prior to treatment was significantly blunted in both
in fact, both the plasma and urinary levels of nitrate didCRF groups, with the GFR increase being of approxi-
not change in patients receiving placebo. The normalmately 20% in patients and 30% in normals. The extent
synthesis of NO also excludes the major influence ofof increment remained unmodified after the six-month
endogenous NOS inhibitors demonstrated in more ad-period of follow-up. Similar data were obtained in the
vanced stages of disease [19].RPF response to amino acid load.
At variance with these data, Noris et al have shown
that plasma collected from patients with end-stage renal
DISCUSSION disease induces NO generation in cultures of endothelial
cells [20]. In that study, however, the level of circulatingThe primary purpose of this study was to evaluate
the systemic ARG/NO pathway in human CRF in basal arginine in patients was almost the double the value
measured in the normal group. This finding is likelyconditions and during prolonged ARG supplementation.
At baseline, as compared with healthy subjects, CRF critical because the activity of inducible NOS strictly
depends on the availability of extracellular arginine [36].patients showed normal values of plasma arginine and
higher citrulline levels. This amino acid profile is consis- In contrast, in our patients with moderate renal failure,
plasma arginine and urinary NO3 were within the normaltent with that previously shown in a large population of
CRF patients [35]. Importantly, the normality of plasma range.
More important insights into the activity of the ARG/arginine levels was associated with a preserved tonic
release of NO; the basal urinary excretion of nitrate was NO pathway in CRF patients derive from the evaluation
of this pathway during ARG treatment. Although thein fact comparable to the value detected in the NOR
group. We also observed an elevation of the plasma placebo group was characterized by a stable NO gen-
eration, the patients receiving supplemental arginineconcentration of NO3 that was likely due to the reduced
renal function. Indeed, as compared with NOR, the renal showed a progressive increment of both the plasma and
urinary levels of NO3 in the absence of changes of renalclearance of NO3 resulted decreased by the same extent
of GFR. Tizianello et al have previously evidenced that function. These data suggest that arginine enhanced the
production of NO. However, the enhancement of NOthe increase of plasma citrulline in CRF patients is not
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synthesis was delayed with respect to the increment of the goal of this study was to detect in patients the antipro-
teinuric response previously demonstrated in remnantplasma arginine. In fact, although the latter value re-
sulted steadily increased by 50% since the second month rats [8–11], rather than testing the impact of ARG on
the rate of GFR decline. It is now recognized that inof follow-up, most of the increment in urinary and plasma
NO3 occurred during the last two months of supplemen- moderate CRF, the urinary protein excretion rate is the
best predictor of progression to end-stage disease [23,tation.
The temporal dissociation between the increase of NO 24]. In these patients, ACEi per se delays renal sclerosis
[38], and the beneficial effect is coupled with the reduc-synthesis and the rise of the plasma levels of its physio-
logic substrate is puzzling. It is possible to hypothesize tion of proteinuria within the first two to three months
of treatment, and the magnitude of the initial antipro-that a conspicuous portion of plasma arginine was con-
stantly shunted into the urea cycle since the beginning teinuric response to ACEi is inversely correlated with
the rate of GFR decline in the subsequent years [23]. Inof treatment; this is indicated by the prompt and stable
increase of blood and urinary levels of urea nitrogen. the CRF-A group, proteinuria remained stable through-
out the six months of observation, indicating the absenceConsistent with this interpretation is the observation that
after six months of ARG, the plasma concentration of of significant influence of ARG on renal prognosis. This
is further supported by the lack of changes in the renalornithine was significantly higher than the basal value.
Hence, the fate of arginine in our patients has been vasodilatory response to an acute amino acid load. RFR
resulted as significantly depressed in CRF patients withpossibly represented by the production of urea, rather
than NO, for almost the entire period of supplementa- respect to normal individuals, as previously demon-
strated by our group [28], and it did not improve follow-tion.
Interestingly, in healthy subjects, intravenous infusion ing ARG supplementation. In contrast, in renal patients
the institution of a therapeutic maneuver effective inof ARG is immediately followed by the parallel increase
of NO3 and cGMP levels, coupled with significant hypo- improving the long-term renal outcome, such as ACEi,
is followed within a short period by the enhancement oftensive as well as renal hemodynamic and tubular effects
[13, 16, 37]. In this study, after oral ARG, the increment RFR coupled with a decrease in protein excretion [25,
26, 39].of NO3 levels was not only delayed, but also not associ-
ated with the expected increase of urinary cGMP. The Interestingly, the lack of changes of RFR in ARG-
treated patients may be, at least partially, also due toincapability of oral arginine to enhance NO generation
may be therefore specifically related to chronic renal the release of Ang II. The CRF-A group was, in fact,
characterized by the elevation of PRA in the absencedisease per se or, alternatively, to the route of adminis-
tration. Definitively, from a clinical point of view, these of changes of the volume status, indicating that ARG
supplementation was directly responsible for activationfindings open the way to further studies aimed at testing
in CRF patients the effectiveness of a treatment with of the renin-angiotensin system. A similar finding has
been attained in NOR subjects after chronic high proteinNO donors rather than with the physiological precursor
of NO. intake [40]. These data are in agreement with recent
experimental studies proposing that the lack of a normalThe final consequence of the inefficacious response of
NO system to ARG was the lack of impact on blood glomerular vasodilating response to amino acid load is
related to the prevalence of Ang II synthesis over NOpressure, proteinuria, and renal function. The absence
of nephroprotective effects of ARG in this study only generation [4, 5, 25].
In conclusion, this study provides, to our knowledgeapparently confutes the positive findings obtained in
remnant rats [8–12]. In the experimental studies, ARG for the first time, evidence that in proteinuric patients
with moderate CRF. (a) The urinary excretion of NO3treatment was immediately started after surgery,
whereas in this work, ARG was initiated a long time is normal, whereas the plasma levels are high, suggesting
that the synthesis of NO is preserved and associated withafter renal injury became established. This may explain
the discrepancy with the data in remnant rats and, more- retention of its end-product. (b) Under unstimulated
conditions, the levels of NO3 do not vary over six monthsover, stimulates the design of further studies on the ef-
fects of NO donors at different stages of renal disease. of observation, testifying a constant release of NO. (c)
Prolonged oral ARG administration does not enhanceOn the other hand, many pathological changes occur in
human CRF, such as tubular atrophy, interstitial fibrosis, NO production, being coupled with a delayed increment
of NO3 levels and no change in urinary cGMP. (d) Theand local hypoxia/ischemia, which are not prominent in
the 5/6 renal ablation model. These abnormalities might inefficacious response results in unmodified renal prog-
nosis, as indicated by the absence of changes in bloodhave contributed to the lack of response to ARG supple-
mentation. pressure, proteinuria, and the lack of improvement of
RFR.Neither of the CRF groups experienced a decrease in
GFR during the six months of observation. Nevertheless, These findings appear essential to the development of
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